These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 24095609)
1. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ; Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. Francis PA Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169 [TBL] [Abstract][Full Text] [Related]
3. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM; J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131 [TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Mathew A; Davidson NE Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743 [TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. O'Regan RM; Zhang Y; Fleming GF; Francis PA; Kammler R; Viale G; Dell'Orto P; Lang I; Bellet M; Bonnefoi HR; Tondini C; Villa F; Bernardo A; Ciruelos EM; Neven P; Karlsson P; Müller B; Jochum W; Zaman K; Martino S; Geyer CE; Jerzak KJ; Davidson NE; Coleman RE; Ingle JN; van Mackelenbergh MT; Loi S; Colleoni M; Schnabel CA; Treuner K; Regan MM JAMA Oncol; 2024 Oct; 10(10):1379-1389. PubMed ID: 39145953 [TBL] [Abstract][Full Text] [Related]
7. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ; J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365 [TBL] [Abstract][Full Text] [Related]
8. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Bui KT; Willson ML; Goel S; Beith J; Goodwin A Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074 [TBL] [Abstract][Full Text] [Related]
9. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM; N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451 [TBL] [Abstract][Full Text] [Related]
10. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients. Abbas W; Rao RR Indian J Cancer; 2019; 56(4):293-296. PubMed ID: 31607695 [TBL] [Abstract][Full Text] [Related]
12. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients]. Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608 [TBL] [Abstract][Full Text] [Related]
13. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Regan MM; Walley BA; Francis PA; Fleming GF; Láng I; Gómez HL; Colleoni M; Tondini C; Pinotti G; Salim M; Spazzapan S; Parmar V; Ruhstaller T; Abdi EA; Gelber RD; Coates AS; Goldhirsch A; Pagani O Ann Oncol; 2017 Sep; 28(9):2225-2232. PubMed ID: 28911092 [TBL] [Abstract][Full Text] [Related]
14. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time? Montagna E; Cancello G; Colleoni M Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM; J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334 [No Abstract] [Full Text] [Related]
16. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. Colleoni M; Munzone E Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891 [TBL] [Abstract][Full Text] [Related]
17. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer. Frampton JE Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573 [TBL] [Abstract][Full Text] [Related]
18. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. Conte B; Poggio F; Del Mastro L Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603 [TBL] [Abstract][Full Text] [Related]
19. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936 [